Latest Ratios: P/E Ratio -15.4x · EV/EBITDA N/A · ROE -35.0%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $710M | $342M | $101M | $90M | $626M | $1.3B | $196M | — | — |
| Enterprise Value | $1.1B | $618M | $295M | $92M | $50M | $579M | $1.2B | $143M | — | — |
| P/E Ratio → | -15.36 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 4.05 | 1.38 | 1.39 | 7.33 | 16.00 | 3.01 | — | — |
| P/B Ratio | 4.78 | 2.72 | 1.69 | 0.78 | 0.41 | 2.02 | 6.46 | 1.84 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 3.49 | 1.25 | 0.77 | 6.77 | 15.27 | 2.20 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 31.7% | 24.8% | 20.5% | 37.0% | 25.6% | 33.9% | 31.3% | -24.9% |
| Operating Margin | — | — | -80.7% | -149.6% | -177.6% | -76.4% | -53.6% | -34.4% | -36.5% | -236.0% |
| Net Profit Margin | — | — | -96.1% | -147.4% | -174.2% | -76.3% | -52.5% | -38.5% | -52.6% | -251.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -35.0% | -35.0% | -48.9% | -62.3% | -42.9% | -25.8% | -27.4% | -16611.9% | — | — |
| ROA | -26.9% | -26.9% | -32.8% | -41.8% | -32.9% | -20.3% | -20.5% | -25.2% | -52.9% | -70.3% |
| ROIC | -40.7% | -40.7% | -37.1% | -55.4% | -39.3% | -24.5% | -33.1% | -31.3% | — | — |
| ROCE | -33.0% | -33.0% | -32.7% | -50.3% | -37.0% | -23.0% | -27.1% | -49.2% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.22 | 0.37 | 0.22 | 0.19 | 0.06 | 0.02 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.35 | -0.23 | -0.07 | -0.19 | -0.15 | -0.30 | -0.50 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -395.34 | -395.34 | -3385.08 | -982.75 | -562.56 | -353.41 | -20610.50 | -21.13 | -9.50 | -17.11 |
Net cash position: cash ($124M) exceeds total debt ($32M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.76 | 6.76 | 6.52 | 3.11 | 6.03 | 10.16 | 5.43 | 2.79 | 0.51 | 0.55 |
| Quick Ratio | 6.61 | 6.61 | 6.39 | 2.99 | 5.83 | 10.03 | 5.37 | 2.77 | 0.47 | 0.53 |
| Cash Ratio | 6.05 | 6.05 | 5.94 | 2.42 | 5.06 | 9.17 | 5.00 | 2.57 | 0.34 | 0.46 |
| Asset Turnover | — | — | 0.31 | 0.33 | 0.22 | 0.22 | 0.32 | 0.41 | 0.91 | 0.28 |
| Inventory Turnover | 8.77 | 8.77 | 14.53 | 9.76 | 8.10 | 13.19 | 21.88 | 30.29 | 12.17 | 14.28 |
| Days Sales Outstanding | — | — | 35.11 | 88.07 | 93.38 | 78.85 | 29.47 | 18.47 | 43.07 | 75.27 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $89M | $59M | $48M | $46M | $44M | $34M | $18M | $22M | $22M |
Liquidity and capital exhaustion
As reported in recent financial statements, Personalis saw gross margins collapse to a nominal 1.8% in 2026Q1, a significant decline from the 35.6% peak observed in 2024Q2, which suggests that the company's high-fixed-cost laboratory infrastructure is currently failing to achieve the necessary scale for profitable operations.
The dramatic contraction in gross margins indicates that the company's sequencing-intensive business model is highly sensitive to volume fluctuations. Investors should monitor whether this margin compression is a temporary byproduct of the current revenue transition or a structural limitation of the NeXT platform's cost profile.
Based on the company's reported figures, ROIC has remained consistently negative, bottoming at -12.7% in 2026Q1, which reflects a sustained inability to generate returns on invested capital that exceed the cost of funding the company's intensive research and development and laboratory infrastructure requirements.
The persistent negative ROIC suggests that the company is currently destroying shareholder value rather than compounding it. This trend warrants further investigation into whether the ongoing strategic pivot toward clinical diagnostics can eventually drive the efficiency gains required to reach a positive return threshold.
According to recent SEC filings, the company's asset turnover ratio remains extremely low at 0.05 in 2026Q1, highlighting a structural inefficiency in how the firm utilizes its significant investment in property, plant, and equipment to generate top-line revenue relative to its industry peers.
The low asset turnover ratio suggests that the company's laboratory capacity is significantly underutilized, which places additional pressure on the bottom line. While the cash conversion cycle has shown some variability, the underlying inability to drive higher revenue per dollar of assets remains a primary concern for long-term operational viability.
As evidenced by the latest quarterly data, the current ratio remains elevated at 6.61, yet this figure masks a rapid depletion of cash reserves, which fell to $73.6 million in 2026Q1, signaling a tightening runway that may necessitate future dilutive capital raises to sustain operations.
While the high current ratio might appear to suggest a strong liquidity position, it is largely a function of the company's current balance sheet structure rather than operational cash generation. Investors should monitor the cash burn rate closely, as the current trajectory suggests that the existing liquidity buffer may be insufficient to reach self-sustaining scale.
The market's reliance on EV/Sales multiples to value Personalis is often misapplied, as it fails to account for the lumpy, project-based nature of the company's revenue and the significant disparity between high-volume, low-margin government contracts and the desired high-margin clinical diagnostic business model.
Using a simple revenue multiple obscures the underlying quality of the earnings, as it treats all revenue streams as equally profitable. A more appropriate approach would involve adjusting for the mix of revenue and focusing on the contribution margin of the clinical diagnostic segment, which is the true driver of long-term value.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PSNL stock.
Personalis, Inc.'s current P/E ratio is -15.4x. This places it at the 50th percentile of its historical range.
Personalis, Inc.'s return on equity (ROE) is -35.0%. The historical average is -40.4%.
Based on historical data, Personalis, Inc. is trading at a P/E of -15.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.